[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:acute-myeloid-leukemia":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":312,"states":398},"Acute Myeloid Leukemia",392,339,[8,16,22,28,35,41,47,53,59,65,72,78,84,90,96,103,109,115,121,127,133,139,145,151,157,163,169,175,181,187,193,200,206,212,218,224,230,236,243,249,254,259,265,271,277,283,289,294,300,306],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05945849","CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory\u002FRelapsed AML",[12],"Phase 1","RECRUITING","2026-08-26T02:18:02.701182Z","2026-07-19T19:36:05.121751Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT03874052","Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[12],"2026-08-26T02:15:50.539717Z","2026-07-19T19:36:05.114969Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT07464951","CART123 Cells With or Without Ruxolitinib in Relapsed\u002FRefractory Acute Myeloid Leukemia",[12],"2026-08-26T02:15:27.567165Z","2026-07-19T19:36:05.074202Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT05401097","IDH Targeted\u002FNon- Targeted vs Non-targeted\u002FIDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)",[32],"Phase 2","2026-08-26T02:15:30.699880Z","2026-07-05T05:32:16.798999Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05355051","A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed\u002FRefractory Hodgkin's Lymphoma",[32],"2026-08-26T02:18:39.640967Z","2026-07-05T05:32:16.798775Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06492707","DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial",[12],"2026-08-03T00:57:52.718762Z","2026-07-05T05:32:16.757562Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06357182","Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia",[12],"2026-08-26T02:16:16.995720Z","2026-07-05T05:32:16.751844Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT06191978","A Phase Ia\u002FIb Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine\u002FCedazuridine (ASTX727) in Pediatric Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia (AML)",[12],"2026-08-26T02:19:13.549512Z","2026-07-05T05:32:16.746311Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT06197672","Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant",[12],"2026-08-26T02:16:41.943926Z","2026-07-05T05:32:16.746249Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":70,"content_modified":71},"NCT06788756","L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory\u002FRelapsed AML",[69],"Phase 2\u002FPhase 3","2026-08-26T02:15:38.131683Z","2026-07-05T05:32:16.694008Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06714591","Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1",[12],"2026-08-26T02:16:50.548894Z","2026-07-05T05:32:16.691656Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT07661095","A Study of CRD3874-SI in People With Leukemia",[12],"2026-08-26T02:15:22.311223Z","2026-07-05T03:45:20.261552Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT07347418","CD64 CAR T Cell Therapy in Adults With Relapsed and\u002For Refractory AML",[12],"2026-08-26T02:16:01.910993Z","2026-06-16T05:54:07.938590Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT07306832","A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)",[12],"2026-08-26T02:17:33.807405Z","2026-06-04T01:30:07.901469Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":101,"content_modified":102},"NCT07591649","Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT",[100],"Phase 1\u002FPhase 2","2026-08-26T02:19:26.493949Z","2026-05-29T15:36:40.202045Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06763341","A Phase 1 Study of AOH1996 in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia",[12],"2026-08-26T02:18:26.932189Z","2026-05-29T15:36:40.170238Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT07566585","Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation",[12],"2026-08-26T02:17:03.534765Z","2026-05-13T02:55:06.731143Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT07012044","A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia",[12],"2026-08-26T02:18:53.782384Z","2026-05-13T02:55:06.607134Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT05703542","BXCL701 Phase 1 R\u002FR Acute Myeloid Leukemia or Myelodysplastic Syndrome",[12],"2026-08-26T02:18:35.425468Z","2026-05-05T02:43:29.711893Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT02781883","Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML",[32],"2026-08-26T02:15:42.447052Z","2026-05-05T02:43:29.706897Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT06511882","Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD",[32],"2026-08-26T02:15:02.712396Z","2026-05-05T02:43:29.703206Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT06782542","Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy",[32],"2026-08-26T02:17:52.450442Z","2026-05-05T02:43:29.682356Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT07283094","FHD-286 With Low-Dose Weekly Decitabine\u002FVenetoclax in Patients With Acute Myeloid Leukemia",[12],"2026-08-26T02:17:41.695983Z","2026-05-05T02:43:29.674771Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT05597306","Venetoclax and Bomedemstat in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia",[12],"2026-08-26T02:15:49.658025Z","2026-05-05T02:43:29.667808Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT07304011","Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent",[32],"2026-08-26T02:16:47.762107Z","2026-05-05T02:43:29.666379Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT05190471","A Clinical Trial of BP1002 in Patients With Refractory\u002FRelapsed Acute Myeloid Leukemia (AML)",[12],"2026-08-26T02:19:09.651016Z","2026-05-05T02:43:29.666364Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT06871410","Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",[12],"2026-08-26T02:19:06.150683Z","2026-05-05T02:43:29.583662Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT06561152","Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML",[100],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:29.534079Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT06616636","A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)",[12],"2026-08-26T02:19:10.436356Z","2026-05-05T02:43:29.528676Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT05580601","Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)",[100],"2026-08-26T02:18:46.948970Z","2026-05-05T02:43:29.501219Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":198,"content_modified":199},"NCT06370000","Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality",[197],"Phase 4","2026-08-26T02:15:01.639696Z","2026-05-05T02:43:29.498927Z",{"nct_id":201,"title":202,"phases":203,"status":13,"updated_at":204,"content_modified":205},"NCT06401603","A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia",[12],"2026-08-26T02:18:43.501109Z","2026-05-05T02:43:29.388278Z",{"nct_id":207,"title":208,"phases":209,"status":13,"updated_at":210,"content_modified":211},"NCT05188170","Niclosamide in Pediatric Patients With Relapsed and Refractory AML",[12],"2026-08-26T02:15:39.267524Z","2026-05-05T02:43:29.350833Z",{"nct_id":213,"title":214,"phases":215,"status":13,"updated_at":216,"content_modified":217},"NCT06672146","Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)",[32],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:29.296381Z",{"nct_id":219,"title":220,"phases":221,"status":13,"updated_at":222,"content_modified":223},"NCT06445959","Phase 1b\u002F2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib",[100],"2026-08-26T02:15:04.877798Z","2026-05-05T02:43:29.294355Z",{"nct_id":225,"title":226,"phases":227,"status":13,"updated_at":33,"content_modified":229},"NCT04293562","A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and\u002For Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations",[228],"Phase 3","2026-05-05T02:43:29.285570Z",{"nct_id":231,"title":232,"phases":233,"status":13,"updated_at":234,"content_modified":235},"NCT07008638","Phase I\u002FII Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)",[100],"2026-08-26T02:18:51.833592Z","2026-05-05T02:43:29.192717Z",{"nct_id":237,"title":238,"phases":239,"status":13,"updated_at":241,"content_modified":242},"NCT07059975","UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML",[240],"Early Phase 1","2026-08-26T02:17:22.949982Z","2026-05-05T02:43:29.190474Z",{"nct_id":244,"title":245,"phases":246,"status":13,"updated_at":247,"content_modified":248},"NCT06419634","Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",[12],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:29.152384Z",{"nct_id":250,"title":251,"phases":252,"status":13,"updated_at":185,"content_modified":253},"NCT06996119","Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant",[12],"2026-05-05T02:43:29.070358Z",{"nct_id":255,"title":256,"phases":257,"status":13,"updated_at":149,"content_modified":258},"NCT06548230","A Phase 1B\u002F2A Trial of NADUNOLIMAB in Combination With Azacitidine (With\u002FWithout Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)",[100],"2026-05-05T02:43:29.069324Z",{"nct_id":260,"title":261,"phases":262,"status":13,"updated_at":263,"content_modified":264},"NCT04905810","Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure",[32],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:29.042264Z",{"nct_id":266,"title":267,"phases":268,"status":13,"updated_at":269,"content_modified":270},"NCT05360160","A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine\u002FCedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)",[100],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:29.040577Z",{"nct_id":272,"title":273,"phases":274,"status":13,"updated_at":275,"content_modified":276},"NCT06429449","Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia",[12],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:28.971708Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":281,"content_modified":282},"NCT06504459","Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML",[32],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:28.882922Z",{"nct_id":284,"title":285,"phases":286,"status":13,"updated_at":287,"content_modified":288},"NCT06440135","Ziftomenib Maintenance Post Allo-HCT",[12],"2026-08-26T02:18:23.582895Z","2026-05-05T02:43:28.881398Z",{"nct_id":290,"title":291,"phases":292,"status":13,"updated_at":216,"content_modified":293},"NCT07130695","Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation",[12],"2026-05-05T02:43:28.846320Z",{"nct_id":295,"title":296,"phases":297,"status":13,"updated_at":298,"content_modified":299},"NCT06313437","Revumenib in Combination With 7+3 + Midostaurin in AML",[12],"2026-08-26T02:16:56.877406Z","2026-05-05T02:43:28.835411Z",{"nct_id":301,"title":302,"phases":303,"status":13,"updated_at":304,"content_modified":305},"NCT06529731","Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation",[32],"2026-08-26T02:16:11.347936Z","2026-05-05T02:43:28.795399Z",{"nct_id":307,"title":308,"phases":309,"status":13,"updated_at":310,"content_modified":311},"NCT04659616","Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia",[12],"2026-08-26T02:15:36.077529Z","2026-05-05T02:43:28.717298Z",[313,317,321,325,329,333,337,341,344,348,351,355,359,363,366,369,372,375,379,382,385,388,392,395],{"biomarker":314,"count":315,"slug":316},"KMT2A Gene",32,"kmt2a-gene",{"biomarker":318,"count":319,"slug":320},"Receptor-Type Tyrosine-Protein Kinase FLT3",31,"receptor-type-tyrosine-protein-kinase-flt3",{"biomarker":322,"count":323,"slug":324},"NPM1 Gene",30,"npm1-gene",{"biomarker":326,"count":327,"slug":328},"IDH1 Gene",22,"idh1-gene",{"biomarker":330,"count":331,"slug":332},"TP53 Gene",20,"tp53-gene",{"biomarker":334,"count":335,"slug":336},"HLA Complex",17,"hla-complex",{"biomarker":338,"count":339,"slug":340},"BCR\u002FABL1 Fusion Gene",12,"bcr-abl1-fusion-gene",{"biomarker":342,"count":339,"slug":343},"IDH2 Gene","idh2-gene",{"biomarker":345,"count":346,"slug":347},"CD33 Gene",11,"cd33-gene",{"biomarker":349,"count":346,"slug":350},"Interleukin-3 Receptor Subunit Alpha","interleukin-3-receptor-subunit-alpha",{"biomarker":352,"count":353,"slug":354},"NUP98 Gene",10,"nup98-gene",{"biomarker":356,"count":357,"slug":358},"MBD5 wt Allele",8,"mbd5-wt-allele",{"biomarker":360,"count":361,"slug":362},"HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain",6,"hla-class-i-histocompatibility-antigen-a-0201-alpha-chain",{"biomarker":364,"count":361,"slug":365},"SF3B1 Gene","sf3b1-gene",{"biomarker":367,"count":361,"slug":368},"SRSF2 Gene","srsf2-gene",{"biomarker":370,"count":361,"slug":371},"U2AF1 Gene","u2af1-gene",{"biomarker":373,"count":361,"slug":374},"U2 Small Nuclear Ribonucleoprotein Auxiliary Factor 35 kDa Subunit-Related Protein 2","u2-small-nuclear-ribonucleoprotein-auxiliary-factor-35-kda-subunit-related-protein-2",{"biomarker":376,"count":377,"slug":378},"Histone-Lysine N-Methyltransferase EZH2",5,"histone-lysine-n-methyltransferase-ezh2",{"biomarker":380,"count":377,"slug":381},"HLA-A Gene","hla-a-gene",{"biomarker":383,"count":377,"slug":384},"MECOM Gene","mecom-gene",{"biomarker":386,"count":377,"slug":387},"RUNX1 Gene","runx1-gene",{"biomarker":389,"count":390,"slug":391},"ASXL1 Gene",4,"asxl1-gene",{"biomarker":393,"count":390,"slug":394},"BCOR Gene","bcor-gene",{"biomarker":396,"count":390,"slug":397},"CD70 Antigen","cd70-antigen",[399,403,407,411,415,419,423,427,431,435,439,443,446,450,454,458,462,465,469,473,477,481,484,487],{"state":400,"count":401,"slug":402},"Texas",139,"texas",{"state":404,"count":405,"slug":406},"California",116,"california",{"state":408,"count":409,"slug":410},"New York",112,"new-york",{"state":412,"count":413,"slug":414},"Florida",83,"florida",{"state":416,"count":417,"slug":418},"Ohio",79,"ohio",{"state":420,"count":421,"slug":422},"Massachusetts",73,"massachusetts",{"state":424,"count":425,"slug":426},"Pennsylvania",65,"pennsylvania",{"state":428,"count":429,"slug":430},"North Carolina",63,"north-carolina",{"state":432,"count":433,"slug":434},"Washington",55,"washington",{"state":436,"count":437,"slug":438},"Illinois",52,"illinois",{"state":440,"count":441,"slug":442},"Georgia",51,"georgia",{"state":444,"count":441,"slug":445},"Tennessee","tennessee",{"state":447,"count":448,"slug":449},"Maryland",49,"maryland",{"state":451,"count":452,"slug":453},"New Jersey",47,"new-jersey",{"state":455,"count":456,"slug":457},"Oregon",44,"oregon",{"state":459,"count":460,"slug":461},"Colorado",41,"colorado",{"state":463,"count":460,"slug":464},"Wisconsin","wisconsin",{"state":466,"count":467,"slug":468},"Michigan",40,"michigan",{"state":470,"count":471,"slug":472},"Minnesota",38,"minnesota",{"state":474,"count":475,"slug":476},"Missouri",37,"missouri",{"state":478,"count":479,"slug":480},"Arizona",34,"arizona",{"state":482,"count":315,"slug":483},"Virginia","virginia",{"state":485,"count":323,"slug":486},"Alabama","alabama",{"state":488,"count":489,"slug":490},"Kansas",27,"kansas"]